Smart Immune SAS
🇫🇷France
- Country
- 🇫🇷France
- Ownership
- Holding
- Established
- 2017-07-17
- Employees
- 11
- Market Cap
- -
- Website
- http://www.smart-immune.com
Clinical Trials
3
Active:0
Completed:0
Trial Phases
2 Phases
Phase 1:2
Not Applicable:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (66.7%)Not Applicable
1 (33.3%)Safety and Efficacy of SMART101 in Adult Patients With Hematological Malignancies After Haploidentical HSCT With Post-transplant Cyclophosphamide
Phase 1
Recruiting
- Conditions
- Hematological Malignancies
- First Posted Date
- 2023-03-14
- Last Posted Date
- 2023-09-25
- Lead Sponsor
- Smart Immune SAS
- Target Recruit Count
- 40
- Registration Number
- NCT05768035
- Locations
- 🇫🇷
Institut Paoli Calmettes, Marseille, France
🇫🇷Centre hospitalier universitaire de Nantes, Nantes, France
🇫🇷Hôpital Saint-Louis, Paris, France
Development of a Cell Culture Process for the Production of Human T-lymphocyte Precursors
Not Applicable
Recruiting
- Conditions
- Healthy Volunteers
- First Posted Date
- 2021-11-11
- Last Posted Date
- 2023-11-21
- Lead Sponsor
- Smart Immune SAS
- Target Recruit Count
- 14
- Registration Number
- NCT05118113
- Locations
- 🇫🇷
CIC Paris Est, Hôpital Pitié Salpêtrière, Paris, France
Safety and Efficacy of SMART101 in Pediatric and Adult Patients With Hematological Malignancies After T Cell Depleted Allo-HSCT
Phase 1
Recruiting
- Conditions
- Hematological Malignancies
- First Posted Date
- 2021-07-13
- Last Posted Date
- 2023-03-06
- Lead Sponsor
- Smart Immune SAS
- Target Recruit Count
- 36
- Registration Number
- NCT04959903
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center (MSKCC), New York, New York, United States
News
No news found